These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11989828)

  • 1. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon.
    Haderslev KV; Jeppesen PB; Hartmann B; Thulesen J; Sorensen HA; Graff J; Hansen BS; Tofteng F; Poulsen SS; Madsen JL; Holst JJ; Staun M; Mortensen PB
    Scand J Gastroenterol; 2002 Apr; 37(4):392-8. PubMed ID: 11989828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.
    Jeppesen PB; Hartmann B; Thulesen J; Graff J; Lohmann J; Hansen BS; Tofteng F; Poulsen SS; Madsen JL; Holst JJ; Mortensen PB
    Gastroenterology; 2001 Mar; 120(4):806-15. PubMed ID: 11231933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone favorably affects bone turnover and bone mineral density in patients with short bowel syndrome undergoing intestinal rehabilitation.
    Tangpricha V; Luo M; Fernández-Estívariz C; Gu LH; Bazargan N; Klapproth JM; Sitaraman SV; Galloway JR; Leader LM; Ziegler TR
    JPEN J Parenter Enteral Nutr; 2006; 30(6):480-6. PubMed ID: 17047171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome.
    Gottschalck IB; Jeppesen PB; Hartmann B; Holst JJ; Henriksen DB
    Scand J Gastroenterol; 2008; 43(11):1304-10. PubMed ID: 18609184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
    Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB
    Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enterotrophic effects of glucagon-like peptide 2 are enhanced by neurotensin.
    Litvak DA; Evers BM; Hellmich MR; Townsend CM
    J Gastrointest Surg; 1999; 3(4):432-39; discussion 439-40. PubMed ID: 10482697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients.
    Naimi RM; Madsen KB; Askov-Hansen C; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
    Regul Pept; 2013 Jun; 184():47-53. PubMed ID: 23501043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density and abstention-induced changes in bone and mineral metabolism in noncirrhotic male alcoholics.
    Laitinen K; Lamberg-Allardt C; Tunninen R; Härkönen M; Välimäki M
    Am J Med; 1992 Dec; 93(6):642-50. PubMed ID: 1466360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.
    Iturrino J; Camilleri M; Acosta A; O'Neill J; Burton D; Edakkanambeth Varayil J; Carlson PJ; Zinsmeister AR; Hurt R
    JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1089-1095. PubMed ID: 26223941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum.
    Sigalet DL; Bawazir O; Martin GR; Wallace LE; Zaharko G; Miller A; Zubaidi A
    Dig Dis Sci; 2006 Sep; 51(9):1557-66. PubMed ID: 16927140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study.
    Madsen KB; Askov-Hansen C; Naimi RM; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
    Regul Pept; 2013 Jun; 184():30-9. PubMed ID: 23511332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutritional markers, not markers of bone turnover, are related predictors of bone mineral density in chronic peritoneal dialysis patients.
    Jeong JU; Lee HK; Kim YJ; Kim JS; Kang SS; Kim SB
    Clin Nephrol; 2010 Nov; 74(5):336-42. PubMed ID: 20979940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon.
    Jeppesen PB; Hartmann B; Thulesen J; Hansen BS; Holst JJ; Poulsen SS; Mortensen PB
    Gut; 2000 Sep; 47(3):370-6. PubMed ID: 10940274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.
    Martin GR; Beck PL; Sigalet DL
    World J Gastroenterol; 2006 Jul; 12(26):4117-29. PubMed ID: 16830359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
    Grinspoon S; Baum H; Lee K; Anderson E; Herzog D; Klibanski A
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3864-70. PubMed ID: 8923830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
    Otto Buczkowska E; Dworzecki T
    Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.